SDI-118 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cognitive Disorders
Conditions
Cognitive Disorders
Trial Timeline
Mar 14, 2019 → Mar 11, 2020
NCT ID
NCT05486195About SDI-118 + Placebo
SDI-118 + Placebo is a phase 1 stage product being developed by AbbVie for Cognitive Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT05486195. Target conditions include Cognitive Disorders.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05486195 | Phase 1 | Completed |
Competing Products
20 competing products in Cognitive Disorders
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aricept (donepezil hydrochloride) + placebo | Eisai | Approved | 85 |
| Donepezil | Eisai | Approved | 85 |
| Aricept | Eisai | Phase 2 | 52 |
| Donanemab + Aducanumab | Eli Lilly | Phase 3 | 77 |
| ABT-126 + Placebo | AbbVie | Phase 2 | 52 |
| ABT-288 Low Dose + Placebo + ABT-288 High Dose | AbbVie | Phase 2 | 52 |
| AZD5213 + AZD5213 + AZD5213 | AstraZeneca | Phase 2 | 52 |
| MK-8931 | Merck | Phase 1 | 33 |
| Nicotine patch + MK-4334 + Placebo patch + Placebo capsule | Merck | Phase 1 | 33 |
| Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2) | Merck | Phase 3 | 77 |
| Rivastigmine | Novartis | Phase 3 | 77 |
| Rivastigmine | Novartis | Approved | 85 |
| Exelon (rivastigmine) + Placebo | Novartis | Approved | 85 |
| Canakinumab | Novartis | Phase 2 | 52 |
| Eviplera | Gilead Sciences | Approved | 84 |
| atorvastatin | Pfizer | Pre-clinical | 22 |
| bosutinib | Pfizer | Phase 1 | 32 |
| Aducanumab + Placebo | Biogen | Phase 2 | 49 |
| BIIB080 + BIIB080-matching placebo | Biogen | Phase 2 | 49 |
| BIIB104 | Biogen | Phase 2 | 49 |